Rico-Fontalvo, JorgeDaza-Arnedo, RodrigoRodríguez-Yánez, TomasSoler, María J.2024-12-162024-12-16202424449032  (Electrónico)https://hdl.handle.net/20.500.12442/16064Dear Editor, we would like to congratulate Dr. Perkovic and colleagues demonstrating that semaglutide reduced by 24% the risk of kidney outcomes and death from cardiovascular causes in persons with type 2 diabetes (T2D) and chronic kidney disease (CKD)1. In SUSTAIN 6, semaglutide showed renal benefits mainly in terms of albuminuria reduction, interestingly the metabolic effects (blood sugar control and body weight) were higher in the 1 mg dose as compared to 0.5 mg2. In concordance, in the SUSTAIN FORTE, the 2 mg weekly dose was also better in metabolic control3, indicating that the effect is in part dose-dependent. In addition, when studying kidney function Shaman et al. found that 1 mg of semaglutide has a higher effect in reducing albuminuria and delaying glomerular filtration rate progression as compared to liraglutide 1.8 mgs/day and low semaglutide dose 0.5 mgs/weekly4.pdfengAttribution-NonCommercial-NoDerivs 3.0 United Statesinfo:eu-repo/semantics/openAccessinfo:eu-repo/semantics/articlehttps://dx.doi.org/10.24875/NEFRO.24000031https://www.nefrologialatinoamericana.com/files/es/nefro_24_21_3_096-097.pdfType 2 diabetesChronic kidney disease